The challenge of managing coexistent type 2 diabetes and obesity

The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition.
Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes.
Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors, and a glucosidase inhibitors are typically weight neutral.
The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients.
New treatments should ideally reduce hyperglycaemia and excess adiposity.
Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.